Page last updated: 2024-08-16

temozolomide and macitentan

temozolomide has been researched along with macitentan in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aldape, K; Choi, HJ; Conrad, CA; Fidler, IJ; He, J; Kim, MS; Kim, SJ; Langley, RR; Lee, HJ; Lehembre, F; Regenass, U; Weinberg, JS; Wu, Q; Yung, WK	1

Other Studies

1 other study(ies) available for temozolomide and macitentan

Article	Year
Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice. Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Oct-15, Volume: 21, Issue:20 Topics: Animals; Cell Division; Cell Line; Cell Line, Tumor; Dacarbazine; Down-Regulation; Endothelial Cells; Endothelin Receptor Antagonists; Female; Glioblastoma; Glioma; Humans; Mice; Mice, Nude; NIH 3T3 Cells; Pyrimidines; Sulfonamides; Temozolomide	2015

Article

Year

Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Oct-15, Volume: 21, Issue:20

Topics: Animals; Cell Division; Cell Line; Cell Line, Tumor; Dacarbazine; Down-Regulation; Endothelial Cells; Endothelin Receptor Antagonists; Female; Glioblastoma; Glioma; Humans; Mice; Mice, Nude; NIH 3T3 Cells; Pyrimidines; Sulfonamides; Temozolomide

2015